近日,一项国产 first-in-class EGFR/HER-3双特异性ADC的首项人体I期临床研究“BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate , in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study.”惊艳亮相2023ASCO会议。
热门推荐: 抗肿瘤 , ADC , HER-3投稿合作联系方式: Kelly.Xiao@imsinoexpo.com 021-33392297
地址:上海市徐汇区虹桥路355号城开国际大厦7-8楼 200030